Take a look at the latest on Palatin across our media publications, posters, and presentations.
The Role of Melanocortin Receptor Agonists in the Treatment of Ocular Disease
Positive results were seen across multiple signs and symptoms of dry eye disease (DED) in a phase 2 study of Palatin Technologies’ MCR pan-agonist, PL9643, in adults with mild, moderate, or severe DED. Continued development of PL9643 as a novel therapy for DED is supported by a planned phase 3 trial comparing PL9643 to vehicle in more than 300 patients with moderate to severe DED.
Therapeutically targeting the melanocortin pathway represents a novel approach to the treatment of ocular diseases. Synthetic MCr receptor agonists show promise in the treatment of uveitis and retinopathy in preclinical animal models and PL9643 has demonstrated efficacy in treating signs and symptoms of dry eye disease in humans.
Protective Effects of Two Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy
Melanocortin agonists have demonstrated anti-inflammatory effects in various experimental models of inflammatory disease. PL8331 and PL9654 are melanocortin 1 receptor agonists being evaluated preclinically for the treatment of various ocular diseases.